Sign In | Join Free | My
Home > Active Pharmaceutical Ingredients >

191732-72-6 Lenalidomide

Guangzhou Meisi New Material Co.,Ltd
Trust Seal
Verified Supplier
Credit Check
Supplier Assessment
    Buy cheap 191732-72-6 Lenalidomide from wholesalers
    Buy cheap 191732-72-6 Lenalidomide from wholesalers
    • Buy cheap 191732-72-6 Lenalidomide from wholesalers

    191732-72-6 Lenalidomide

    Ask Lasest Price
    Brand Name : Meisi New Material
    Payment Terms : T/T
    Delivery Time : 5-8work days
    • Product Details
    • Company Profile

    191732-72-6 Lenalidomide

    Lenalidomide CAS No.191732-72-6

    Product Name: Lenalidomide
    Full English name:(3S)-3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione

    Chemical name: (3S) - 3 - (4-amino-1-oxo-1,3-dihydro-2h-isoindole-2-yl) piperidine-2,6-dione; (3S) - 3 - (4-amino-1-oxo-2-isoindolin) piperidine-2,6-dione

    CAS No:191732-72-6
    Molecular formula : C13H13N3O3
    Molecular weight : 259.26062

    Physical and chemical properties:

    Melting point 269-271 ° C, density 1.460 ± 0.06 g / cm3.

    Product category:

    Lenalidomide is an anti-tumor drug developed by celgene biopharmaceutical company in the United States. Its chemical structure is similar to thalidomide, and it has multiple functions such as anti-tumor, immune regulation and anti angiogenesis. It can inhibit the secretion of pro-inflammatory cytokines and increase the secretion of anti-inflammatory cytokines of peripheral blood monocytes. In vitro experiments showed that the product could inhibit the proliferation of some cell lines such as Namalwa cells. Lenalidomide can inhibit the growth of multiple myeloma cells and MM1S cells. In addition, the product can also inhibit the expression of cyclooxygenase 2 (COX-2), but has no effect on COX-1. Two multicenter, randomized, blind, placebo-controlled clinical studies evaluated the safety and efficacy of lenalidomide in the treatment of multiple myeloma. The main outcome of the study was the mid-term analysis of TTP. The results showed that TTP in the combination group was significantly superior to that in the dexamethasone group. Recent clinical studies have shown that lenalidomide can be used in the treatment of MDS and mm as well as myeloma, leukemia, metastatic renal cancer, solid tumor, primary systemic amyloidosis and systemic myelofibrosis with myelometaplasia. Lenalidomide is a new generation derivative of thalidomide, but it has not been found that it has teratogenic toxicity, and its efficacy is 100 times stronger than thalidomide. According to the results of phase III clinical trials, lenalidomide is the most effective drug in the treatment of multiple myeloma. More than half of the patients can prolong their survival time to more than 3 years after taking the drug. In addition, it is also the only drug that can effectively treat myelodysplastic syndrome (MDS). Clinical results show that 64% of MDS patients use naduramine to treat MDS without blood transfusion.

    Quality 191732-72-6 Lenalidomide for sale
    Inquiry Cart 0
    Send your message to this supplier
    *To: Guangzhou Meisi New Material Co.,Ltd
    Characters Remaining: (0/3000)

    Home| Products| Suppliers| Quality Suppliers| Site Map |About Us |Contact Us |Help |关于我们 |联系我们

    Copyright © 2009 - 2020 All rights reserved.